Sample Page
Author:
Fulcrum Therapeutics, Inc.
Posted Date:
May 8, 2026
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc.
May 8, 2026
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Fulcrum Therapeutics, Inc.
April 27, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Fulcrum Therapeutics, Inc.
April 27, 2026
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Fulcrum Therapeutics, Inc.
April 20, 2026
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Fulcrum Therapeutics, Inc.
March 19, 2026
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc.
March 6, 2026
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, Inc.
March 3, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
Fulcrum Therapeutics, Inc.
February 24, 2026
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics, Inc.
February 24, 2026
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics, Inc.
February 17, 2026
1
2
Next
